Related Experiment Video
Updated: Jun 1, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
Anna R Carta1, Augusta Pisanu, Ezio Carboni
1Department of Toxicology, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
Parkinson'S Disease
|May 24, 2011
Summary
Thiazolidinediones (PPAR)-γ agonists show neuroprotective effects in Parkinson's disease models by reducing inflammation. Targeting immune responses offers a potential therapeutic strategy for Parkinson's disease.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists used for type 2 diabetes.
- PPAR-γ agonists exhibit neuroprotective properties in neurodegenerative diseases, including Parkinson's disease (PD).
- Neuroinflammation, involving microglia and T cells, is implicated in PD pathogenesis and dopaminergic degeneration.
Purpose of the Study:
- To review preclinical evidence of PPAR-γ-induced neuroprotection in experimental PD models.
- To highlight anti-inflammatory mechanisms of PPAR-γ agonists in PD.
- To explore the potential of targeting immune functions for novel PD therapies.
Main Methods:
- Review of preclinical studies on PPAR-γ agonists in PD models.
- Analysis of anti-inflammatory mechanisms involving central and peripheral immunomodulation.
- Examination of PPAR-γ expression and function in immune cells.
Main Results:
- Preclinical evidence supports PPAR-γ-induced neuroprotection in experimental PD.
- PPAR-γ agonists modulate microglial activation, monocyte, and T cell differentiation.
- Anti-inflammatory effects involve both central and peripheral immunomodulatory activities.
Conclusions:
- PPAR-γ agonists demonstrate therapeutic potential for PD through anti-inflammatory actions.
- Targeting immune-mediated neuroinflammation, centrally or peripherally, is a promising strategy.
- Modulating PPAR-γ offers a novel approach for disease-modifying therapies in PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...